We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
In the latest close session, Medtronic (MDT - Free Report) was down 1.81% at $91.22. This move lagged the S&P 500's daily gain of 0.32%. Elsewhere, the Dow saw an upswing of 0.3%, while the tech-heavy Nasdaq appreciated by 0.66%.
Shares of the medical device company have appreciated by 10.31% over the course of the past month, outperforming the Medical sector's gain of 6.56%, and the S&P 500's gain of 3.34%.
The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on September 1, 2026. It is anticipated that the company will report an EPS of $1.39, marking a 10.32% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $9.47 billion, showing a 10.4% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $5.94 per share and a revenue of $38.64 billion, signifying shifts of +7.41% and +6.26%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Medtronic. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Currently, Medtronic is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Medtronic is presently being traded at a Forward P/E ratio of 15.63. Its industry sports an average Forward P/E of 21.32, so one might conclude that Medtronic is trading at a discount comparatively.
It's also important to note that MDT currently trades at a PEG ratio of 2.49. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry had an average PEG ratio of 2.12 as trading concluded yesterday.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 101, putting it in the top 42% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Medtronic (MDT) Stock Dips While Market Gains: Key Facts
In the latest close session, Medtronic (MDT - Free Report) was down 1.81% at $91.22. This move lagged the S&P 500's daily gain of 0.32%. Elsewhere, the Dow saw an upswing of 0.3%, while the tech-heavy Nasdaq appreciated by 0.66%.
Shares of the medical device company have appreciated by 10.31% over the course of the past month, outperforming the Medical sector's gain of 6.56%, and the S&P 500's gain of 3.34%.
The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on September 1, 2026. It is anticipated that the company will report an EPS of $1.39, marking a 10.32% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $9.47 billion, showing a 10.4% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $5.94 per share and a revenue of $38.64 billion, signifying shifts of +7.41% and +6.26%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Medtronic. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Currently, Medtronic is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Medtronic is presently being traded at a Forward P/E ratio of 15.63. Its industry sports an average Forward P/E of 21.32, so one might conclude that Medtronic is trading at a discount comparatively.
It's also important to note that MDT currently trades at a PEG ratio of 2.49. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry had an average PEG ratio of 2.12 as trading concluded yesterday.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 101, putting it in the top 42% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.